Aside from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and fit enough to tolerate FCR therapy, should be fantastic candidates to the latter, Using the benefit remaining that this treatment method could be completed in six months whilst ibrutinib must be taken indefinitely. This feature could be particularly precious for non-compliant